Evidence map›Paper›PMID 31798589›Full record

ArticleFrontiers in immunology2019

Recombinant Haemagglutinin Derived From the Ciliated Protozoan

Karina Jawinski, Marcus Hartmann, Charanjit Singh, Ekaterina Kinnear, David C Busse, Annalisa Ciabattini, Fabio Fiorino, Donata Medaglini, Claudia Maria Trombetta, Emanuele Montomoli and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 3 countries.

Karina JawinskiCilian AG, Munster, Germany.
Marcus HartmannCilian AG, Munster, Germany.
Charanjit SinghDepartment of Infectious Disease, St Mary's Campus, Imperial College London, London, United Kingdom.
Ekaterina KinnearDepartment of Infectious Disease, St Mary's Campus, Imperial College London, London, United Kingdom.
David C BusseDepartment of Infectious Disease, St Mary's Campus, Imperial College London, London, United Kingdom.
Annalisa CiabattiniLaboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy.
Fabio FiorinoLaboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy.
Donata MedagliniLaboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy.
Claudia Maria TrombettaDepartment of Molecular and Developmental Medicine, University of Siena, Siena, Italy.
Emanuele MontomoliDepartment of Molecular and Developmental Medicine, University of Siena, Siena, Italy.
Vanessa ContrerasCEA-Université Paris Sud 11-INSERM U1184, Immunology of Viral Infections and Autoimmune Diseases, IDMIT Department, IBFJ, Le Kremlin-Bicêtre, France.
Roger Le GrandCEA-Université Paris Sud 11-INSERM U1184, Immunology of Viral Infections and Autoimmune Diseases, IDMIT Department, IBFJ, Le Kremlin-Bicêtre, France.
Celine CoiffierLaboratoire de Biologie Tissulaire et d'Ingénierie Thérapeutique, UMR 5305, Université Lyon 1, CNRS, IBCP, Lyon, France.
Charlotte PrimardAdjuvatis, Lyon, France.
Bernard VerrierAdjuvatis, Lyon, France.
John S TregoningDepartment of Infectious Disease, St Mary's Campus, Imperial College London, London, United Kingdom.
Imperial College London · GBUniversity of Siena · ITBiologie Tissulaire et Ingénierie Thérapeutique · FRCommissariat à l'Énergie Atomique et aux Énergies Alternatives · FRInserm · FRVisMederi Research · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Current influenza vaccines manufactured using eggs have considerable limitations, both in terms of scale up production and the potential impact passaging through eggs can have on the antigenicity of the vaccine virus strains. Alternative methods of manufacture are required, particularly in the context of an emerging pandemic strain. Here we explore the production of recombinant influenza haemagglutinin using the ciliated protozoan

Indexed as

AnimalsAntibodies, ViralDogsFemaleHemagglutinin Glycoproteins, Influenza VirusInfluenza VaccinesMacacaMadin Darby Canine Kidney CellsMiceMice, Inbred BALB CNod2 Signaling Adaptor ProteinOrthomyxoviridae InfectionsPolyestersRecombinant ProteinsTetrahymena thermophilaAntibodies, ViralHemagglutinin Glycoproteins, Influenza VirusInfluenza VaccinesNod2 Signaling Adaptor ProteinPolyesterspoly(lactide)Recombinant Proteinsadjuvantinfluena virusnanoparticleprotozoavaccine manufacture

Identifiers

PMID31798589
PMCPMC6863932
OpenAlexW2989318081

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.